AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently announced primary analysis of TIVO-3 trial’s positive topline results. It is the randomized, open-label, multi-center, controlled, and Phase-3 study involving comparison of tivozanib with sorafenib in 351 participants suffering from metastatic renal cell carcinoma (RCC) or highly refractory renal cell carcinoma.
TIVO-3 trial demonstrates significant benefits in PFS
The trial met its primary endpoint by demonstrating significant benefit statistically in the progression-free survival (PFS). The trial demonstrated that Tivozanib can bring an improvement of 44% in median PFS and also reduces the progression of the carcinoma cells or towards death by 26%. Compared to 3.9 months PFS for sorafenib, the company worked on 5.6 months median PFS for tivozanib. The patients with RCC participating in the TIVO-3 trial previously failed two prior regimes at least.
Out of these patients, around 26% underwent checkpoint inhibitor therapy in the previous lines of treatment. As compared to sorafenib the Tivozanib PFS for patients receiving and not receiving checkpoint inhibitor therapy was much longer. The secondary endpoint for the overall survival (OS) did not reveal expected maturity at the final PFS analysis time demonstrating only 46% potential of OS events. During the preliminary OS analysis, the OS did not display any significant statistical difference.
Aveo plans final survival analysis in August 2019
As per the protocol the final survival analysis will take place in August next year, exactly two years after the patients enrolled with the trial. The company will submit the detailed results for presentation at a major medical meeting soon. The trial revealed that the overall response rate’s secondary endpoint for patients taking Tivozanib was 18% whereas it was 8% for patients who received sorafenib.
The trial reports indicate that the RCC patients and the grade 3 or patients who faced even higher adverse events in the previous tivozanib trails tolerated tivozanib well. According to Aveo’s president and chief executive officer, Michael Bailey, “We owe our deepest gratitude to the healthcare professionals, many of whom long believed in the potential of tivozanib, and to the patients and their families for participating in our pivotal studies.”
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.